Abeona Therapeutics Announces Closing of $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Abeona Therapeutics Inc. (Nasdaq: ABEO) has successfully completed a registered direct offering, raising an impressive $25 million in gross proceeds. What's even more remarkable is that this offering was carried out without any discounts or warrant coverage, highlighting the unwavering confidence of existing institutional investors in Abeona. The purpose behind this fundraising success is to pre..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 7. 10.
  • textsms

Gene Editing Race Between Editas and Vertex, CRISPR Heats Up

Gene editing companies Editas Medicine, Vertex Pharmaceuticals and CRISPR Therapeutics are all racing to develop treatments for sickle cell disease (SCD) and transfusion-dependent beta thalassemia. Editas recently unveiled early data from its RUBY and EdiTHAL trials, demonstrating the potential of its gene editor EDIT-301 in treating these diseases. However, Vertex and CRISPR also released posit..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 12.
  • textsms